Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report
<h3>Introduction</h3><p dir="ltr">Polycythemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells. The presence of JAK2 mutation is detected in up to 99% of patients with PV. Pruritis is commonly e...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Published: |
2021
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513564284289024 |
|---|---|
| author | Abdulrahman F. Al-Mashdali (16322744) |
| author2 | Waail R. Kashgary (16322746) Mohamed A. Yassin (16322749) |
| author2_role | author author |
| author_facet | Abdulrahman F. Al-Mashdali (16322744) Waail R. Kashgary (16322746) Mohamed A. Yassin (16322749) |
| author_role | author |
| dc.creator.none.fl_str_mv | Abdulrahman F. Al-Mashdali (16322744) Waail R. Kashgary (16322746) Mohamed A. Yassin (16322749) |
| dc.date.none.fl_str_mv | 2021-11-05T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1097/md.0000000000027722 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Ruxolitinib_a_JAK2_inhibitor_as_an_emerging_therapy_for_refractory_pruritis_in_a_patient_with_low-risk_polycythemia_vera_A_case_report/23361755 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis Case report polycythemia vera pruritis Ruxolitinib |
| dc.title.none.fl_str_mv | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Introduction</h3><p dir="ltr">Polycythemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells. The presence of JAK2 mutation is detected in up to 99% of patients with PV. Pruritis is commonly encountered in patients with PV and is considered the most troublesome symptom. Multiple treatment modalities are used for treatment; however, their efficacy is variable. Sometimes, pruritis will not improve even by the use of combined therapies. Recently, Ruxolitinib (a JAK2 inhibitor) has been shown to be very effective, especially in patients with refractory pruritis in the setting of other treatment modalities failure.</p><h3>Patient concern</h3><p dir="ltr">We describe a 55-year-old male with history of low risk PV presented with severe itching despite using different therapies, including phlebotomy and hydroxyurea. His laboratory results on presentation were significant for red blood cells (RBC) of 8.2 × 106/uL (normal = 4.5–5.5), hematocrit (Hct) of 52.8% (normal = 40–50%), platelet count of 519 × 103/uL (normal = 150–400), white blood cells count of 12.3 × 103/uL (normal = 4–10), and basophils count of 0.22 × 103/uL (normal < 0.1).</p><h3>Diagnosis</h3><p dir="ltr">PV related refractory pruritis.</p><h3>Intervention</h3><p dir="ltr">Pruritis improved dramatically after starting Ruxolitinib therapy with an improvement of hematological parameters (both hematocrit and platelet count).</p><h3>Conclusion</h3><p dir="ltr">Different treatment modalities have shown to be beneficial in treating PV-related pruritis, but the clinical outcomes are highly variable. This case report aims to shed light on Ruxolitinib as an emerging therapy for the treatment of refractory cases of PV-related pruritis.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1097/md.0000000000027722" target="_blank">http://dx.doi.org/10.1097/md.0000000000027722</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_03aec05b9b46b633fea1d0ae4bbda2f2 |
| identifier_str_mv | 10.1097/md.0000000000027722 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/23361755 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case reportAbdulrahman F. Al-Mashdali (16322744)Waail R. Kashgary (16322746)Mohamed A. Yassin (16322749)Biomedical and clinical sciencesCardiovascular medicine and haematologyOncology and carcinogenesisCase reportpolycythemia verapruritisRuxolitinib<h3>Introduction</h3><p dir="ltr">Polycythemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells. The presence of JAK2 mutation is detected in up to 99% of patients with PV. Pruritis is commonly encountered in patients with PV and is considered the most troublesome symptom. Multiple treatment modalities are used for treatment; however, their efficacy is variable. Sometimes, pruritis will not improve even by the use of combined therapies. Recently, Ruxolitinib (a JAK2 inhibitor) has been shown to be very effective, especially in patients with refractory pruritis in the setting of other treatment modalities failure.</p><h3>Patient concern</h3><p dir="ltr">We describe a 55-year-old male with history of low risk PV presented with severe itching despite using different therapies, including phlebotomy and hydroxyurea. His laboratory results on presentation were significant for red blood cells (RBC) of 8.2 × 106/uL (normal = 4.5–5.5), hematocrit (Hct) of 52.8% (normal = 40–50%), platelet count of 519 × 103/uL (normal = 150–400), white blood cells count of 12.3 × 103/uL (normal = 4–10), and basophils count of 0.22 × 103/uL (normal < 0.1).</p><h3>Diagnosis</h3><p dir="ltr">PV related refractory pruritis.</p><h3>Intervention</h3><p dir="ltr">Pruritis improved dramatically after starting Ruxolitinib therapy with an improvement of hematological parameters (both hematocrit and platelet count).</p><h3>Conclusion</h3><p dir="ltr">Different treatment modalities have shown to be beneficial in treating PV-related pruritis, but the clinical outcomes are highly variable. This case report aims to shed light on Ruxolitinib as an emerging therapy for the treatment of refractory cases of PV-related pruritis.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1097/md.0000000000027722" target="_blank">http://dx.doi.org/10.1097/md.0000000000027722</a></p>2021-11-05T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1097/md.0000000000027722https://figshare.com/articles/journal_contribution/Ruxolitinib_a_JAK2_inhibitor_as_an_emerging_therapy_for_refractory_pruritis_in_a_patient_with_low-risk_polycythemia_vera_A_case_report/23361755CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/233617552021-11-05T06:00:00Z |
| spellingShingle | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report Abdulrahman F. Al-Mashdali (16322744) Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis Case report polycythemia vera pruritis Ruxolitinib |
| status_str | publishedVersion |
| title | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report |
| title_full | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report |
| title_fullStr | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report |
| title_full_unstemmed | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report |
| title_short | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report |
| title_sort | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis Case report polycythemia vera pruritis Ruxolitinib |